Savant's PRIOR post converted to readable Black text: --->Organovo and Its Customers Present Data Supporting 3D Bioprinted Liver Tissues for Drug Toxicity Testing and Liver Fibrosis Modeling
SAN DIEGO, March 10, 2016 (GLOBE NEWSWIRE) --
Organovo Holdings, Inc. (NYSE MKT:ONVO) ("Organovo"), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced five presentations at the Society of Toxicology's ("SOT") 55th Annual Meeting and ToxExpo, March 13--17, 2016, in New Orleans. These presentations demonstrate the broad applicability of Organovo's exVive3D(TM) Human Liver Model for the assessment of drug safety and the detection of multiple clinically-relevant modes of liver injury, including steatosis and fibrosis. In addition, Organovo's exhibitor-hosted session on March 15, at 9:00 a.m. Central Time (CT), in Room 212 will include oral presentations on recent advances using bioprinted 3D human liver tissues to assess drug-induced liver toxicity.
"Drug-induced liver injury remains a major cause of late-stage clinical failures and market withdrawal, often due to poor translation from preclinical animal studies to clinical outcomes," said Dr. Sharon Presnell, chief technology officer and executive vice president of research & development, Organovo. "Organovo's exVive3D human liver model replicates complex cell-cell interactions and key elements of native tissue architecture to enable the detection of multiple clinically-relevant modes of tissue injury, including necrosis, immune-mediated tissue damage, steatosis, and fibrosis. When a preclinical or clinical-stage asset presents a challenging safety or efficacy signal, exVive3D provides the unique resolving power of a controlled human tissue microenvironment to investigate mechanism and develop solutions."
"Organovo's exVive3D Human Liver Model provides an accurate, predictive and reproducible model of human liver biology for preclinical toxicity testing," said Paul Gallant, general manager, Organovo. "At the SOT Annual Meeting, we and our pharmaceutical customers will be highlighting recent results that show our 3D bioprinted human liver tissue effectively models in vivo tissue composition and physiology."
The presented data supports the use of the exVive3D Human Liver Model in:
-- Investigating in vitro mechanisms of drug-induced liver injury with biochemical and histologic endpoints; -- Evaluating liver toxicity caused by long-term compound treatment, as well as liver recovery following drug removal; -- Capturing the spectrum of drug-induced changes at the tissue level, including reduced liver function and vascular remodeling; -- Demonstrating drug-, chemical-, and TGF-b1-induced liver fibrosis at the cellular, molecular and histologic level; -- Interrogating and identifying over time the key cellular and molecular events underlying fibrogenesis; -- Characterizing the short and long-term effects of acetaminophen; and -- Examining immune-mediated, drug-induced liver injury.
The presentations are as follows:
Exhibitor-hosted Session: March 15, 9:00 a.m. - 10:00 a.m. CT, Room 212
-----------
Title: Advances in the Use of Bioprinted 3D Human Liver Tissues for the Assessment of Drug Induced Liver Toxicity
Presenters: Sharon Collins Presnell, Ph.D., Organovo
Umesh M. Hanumegowda, MVSc Ph.D. DABT, Bristol-Myers Squibb
Poster Presentations: March 15, 9:30 a.m. - 12:45 p.m. CT, CC Exhibit Hall
----------------------
Title: Functional Evaluation of Bioprinted Human Liver Organoid as a Liver Injury Model
Presenter: Kazuhiro Tetsuka, Ph.D., Astellas Pharma Inc.
Poster: 2001: Poster Board - P405
-------------------------------
Title: Modeling Drug Induced Hepatic Fibrosis In Vitro Using Three-Dimensional Liver Tissue Constructs
Presenter: Leah M. Norona, Doctoral Candidate, The University of North Carolina at Chapel Hill and The
Hamner Institutes
Poster: 1996: Poster Board - P348
---------------------------------
Title: Utilization of exVive3D Human Liver Tissues for the Evaluation of Valproic Acid Induced Liver Injury
Presenter: Candace Grundy, Organovo
Poster: 2003: Poster Board - P407
___________________________________
Title: Inflammatory Response of Kupffer Cells in 3D Bioprinted Human Liver Tissues
Presenter: Rhiannon N. Hardwick, Ph.D., Organovo
Poster: 1959: Poster Board - P311
Late-breaking Poster Presentation: March 17, 9:30 a.m. - 12:45 p.m. CT, Great Hall A
____________________________________________________
Title: Monocrotaline Toxicity in 3D Bioprinted Human Liver Tissue
Presenter: Umesh M. Hanumegowda, MVSc Ph.D. DABT, Bristol-Myers Squibb
Poster: 3562: Poster Board - P254
Exhibit Booth: March 14-16, 9:15 a.m. - 4:30 p.m. CT, Booth 1701, CC Exhibit Hall |
